Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

PRODUCTION OF INTERLEUKIN-6 BY RESTING HYBRIDOMA ENDOTHELIAL CELLS OF THE EA.HY926 LINE

DOI: https://doi.org/10.29296/25877313-2022-05-02
Download full text PDF
Issue: 
5
Year: 
2022

U.R. Saginbaev
Post-graduate Student, Department of Biochemistry,
Institute of Experimental Medicine (St. Petersburg, Russia)
https://orcid.org/0000-0001-9709-1882
E-mail: starosta-mpf@mail.ru

Relevance. To study the mechanisms of atherogenesis, experimental models of cell culture (from the umbilical vein (HUVEC) and EA.Hy926 line cells, which are a hybrid of endotheliocytes from the umbilical vein and lung carcinoma), are widely used. The degree of effect of both individual and group cytokines on endotheliocyte physiology can be determined by adding adequate concentrations of mediators to the cell culture. However, to obtain correct results, it is necessary to determine the initial background cytokine concentration characteristic of this cell culture. The purpose of this work was to study the concentration of interleukin 6 in the culture of EA.Hy926 cells. Material and methods. The material was cell cultures of the EA.Hy926 line, which are a hybridoma of endotheliocytes from the umbilical vein (HUVEC) and lung carcinoma (A549). Results. A concentration of IL-6 was found that exceeded by more than an order of magnitude the level of this cytokine in the blood of a healthy person. Cоnclusion. Thus, when assessing the level of proinflammatory cytokine in the cell model, significant excesses were noted, which requires taking this factor into account during experimental work.

Keywords: 
interleukin 6
endothelium
EA.Hy926
experimental model.

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Mishlanov V.Ju., Tuev A.V., Chereshnev V.A. Ateroskleroz: novoe v patogeneze, diagnostike i lechenii (lejkocitarno-lipoproteinovaja teorija): monografija. M.: RAN, 2018; 128.
  2. Armitage J., Holmes M.V., Preiss D. Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week. J. Am. Coll. Cardiol. 2019; 73: 477–487.
  3. Huang L.H. Interleukin-17 drives interstitial entrapment of tissue lipoproteins in experimental psoriasis. Cell Metabol. 2019; 29: 475–487.
  4. Shorstova O.V., Lejfer E.V. Rol' vasa vasorum v patogeneze ateroskleroza. Universitetskaja medicina Urala. 2020; 1: 43–44.
  5. Stefan R.J. Interleukin-6 family cytokines. Cold Spring Harb. Perspect Biol. 2018; 10(2): 028415.
  6. Ershler W.B. Interleukin-6: a cytokine for gerontologists. J. Am. Geriatr. Soc. 1993; 41(2): 176–81.
  7. Pura M.C., Scheele C. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J. 2013; 280(17): 4131–48.
  8. Gordeeva E.K., Kade A.H. Korrekcija citokinovogo i gormonal'nogo disbalansa pri lechenii stabil'noj stenokardii naprjazhenija. Kubanskij nauchnyj medicinskij vestnik. 2018; 25(3): 51–55.